Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RZLT Stock Forecast 2026-2027
$4.61
Current Price
$443.91M
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RZLT Price Targets
+203.7%
To High Target of $14.00
+30.2%
To Median Target of $6.00
-13.2%
To Low Target of $4.00
RZLT Price Momentum
-2.9%
1 Week Change
-8.2%
1 Month Change
-14.5%
1 Year Change
+95.3%
Year-to-Date Change
-59.8%
From 52W High of $11.46
+330.8%
From 52W Low of $1.07
📊 TOP ANALYST CALLS
Did RZLT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rezolute is one of their latest high-conviction picks.
Latest RZLT Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, RZLT has a bullish consensus with a median price target of $6.00 (ranging from $4.00 to $14.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $4.61, the median forecast implies a 30.2% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 203.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RZLT Analyst Ratings
8
Buy
2
Hold
0
Sell
RZLT Price Target Range
Low
$4.00
Average
$6.00
High
$14.00
Current: $4.61
Latest RZLT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RZLT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 15, 2026 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $11.00 |
| Jun 3, 2026 | Maxim Group | Buy | Maintains | $N/A | |
| Jun 3, 2026 | Citizens | Market Outperform | Upgrade | $N/A | |
| Jun 3, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 2, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 14, 2026 | Maxim Group | Buy | Maintains | $N/A | |
| Mar 25, 2026 | Wedbush | Outperform | Upgrade | $N/A | |
| Jan 8, 2026 | Wedbush | Neutral | Maintains | $N/A | |
| Jan 8, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Dec 12, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Dec 12, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 20, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Oct 29, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Sep 22, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Sep 19, 2025 | Maxim Group | Buy | Maintains | $N/A | |
| Sep 18, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Sep 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Rezolute, Inc. (RZLT) Competitors
The following stocks are similar to Rezolute based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rezolute, Inc. (RZLT) Financial Data
Rezolute, Inc. has a market capitalization of $443.91M with a P/E ratio of -4.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -81.7%.
Valuation Metrics
Market Cap
$443.91M
Enterprise Value
$345.93M
P/E Ratio
-4.7x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+27.1%
Current Ratio
15.8x
Debt/Equity
1.0x
ROE
-81.7%
ROA
-48.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rezolute, Inc. (RZLT) Business Model
About Rezolute, Inc.
What They Do
Develops therapies for rare diseases and hypoglycemia.
Business Model
Rezolute, Inc. generates revenue by developing and commercializing innovative therapies for rare diseases, specifically targeting conditions like hyperinsulinism and diabetic macular edema. Their lead asset, ersodetug, is in Phase 3 trials and aims to address unmet medical needs, potentially leading to lucrative market opportunities upon successful approval.
Additional Information
Founded in 2010 and based in Redwood City, California, Rezolute focuses on biologic and small molecule therapies for severe conditions. With a strong emphasis on addressing critical healthcare gaps in rare metabolic and ophthalmologic disorders, the company is positioned for growth in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
75
CEO
Mr. Nevan Charles Elam J.D.
Country
United States
IPO Year
2012
Website
www.rezolutebio.comRezolute, Inc. (RZLT) Latest News & Analysis
Latest News
Quick Summary
Rezolute, Inc. presented data on congenital hyperinsulinism at the ENDO Annual Meeting, including Phase 3 sunRIZE study results and findings from its Expanded Access Program.
Why It Matters
Rezolute's presentations on congenital hyperinsulinism and positive Phase 3 study results could signal advancements in treatment, potentially enhancing its market position and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rezolute, Inc. reported that six of eight participants in its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism met the primary endpoint.
Why It Matters
The positive interim results from Rezolute's Phase 3 study may boost investor confidence, indicating potential efficacy of ersodetug and enhancing the company's market value.
Source: Benzinga
Market Sentiment:
Positive
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
1 month ago
Quick Summary
Rezolute, Inc. reports 50% enrollment in its Phase 3 study of ersodetug for refractory hypoglycemia, with 6 of 8 participants meeting primary endpoint criteria. Topline results expected in H2 2026.
Why It Matters
Rezolute's interim results show strong responder rates in its Phase 3 study, potentially indicating a successful treatment for a rare disease, which could boost the company's stock value and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
1 month ago
Quick Summary
Rezolute, Inc. (Nasdaq: RZLT) will present four studies at the Endocrine Society's Annual Meeting in Chicago from June 13-16, 2026, focusing on treatments for refractory hypoglycemia.
Why It Matters
Rezolute's upcoming presentations at ENDO could highlight advancements in their treatment for refractory hypoglycemia, potentially attracting investor interest and impacting stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rezolute's stock surged 38% in one week following interim upLIFT data indicating that most tumor HI patients reduced or eliminated IV glucose support.
Why It Matters
Rezolute's 38% surge indicates strong investor confidence in positive clinical trial outcomes, suggesting potential market success and increased future revenues.
Source: Zacks Investment Research
Market Sentiment:
Positive
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
2 months ago
Quick Summary
Rezolute, Inc. (Nasdaq: RZLT) reported its financial results and business update for Q1 2026, focusing on treatments for hypoglycemia linked to hyperinsulinism.
Why It Matters
Rezolute's financial results and updates on its rare disease treatments can influence stock performance, indicating potential growth or risks in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RZLT Stock
What is Rezolute, Inc.'s (RZLT) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Rezolute, Inc. (RZLT) has a median price target of $6.00. The highest price target is $14.00 and the lowest is $4.00.
Is RZLT stock a good investment in 2027?
According to current analyst ratings, RZLT has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RZLT stock?
Wall Street analysts predict RZLT stock could reach $6.00 in the next 12 months. This represents a 30.2% increase from the current price of $4.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rezolute, Inc.'s business model?
Rezolute, Inc. generates revenue by developing and commercializing innovative therapies for rare diseases, specifically targeting conditions like hyperinsulinism and diabetic macular edema. Their lead asset, ersodetug, is in Phase 3 trials and aims to address unmet medical needs, potentially leading to lucrative market opportunities upon successful approval.
What is the highest forecasted price for RZLT Rezolute, Inc.?
The highest price target for RZLT is $14.00 from Douglas Tsao at HC Wainwright & Co., which represents a 203.7% increase from the current price of $4.61.
What is the lowest forecasted price for RZLT Rezolute, Inc.?
The lowest price target for RZLT is $4.00 from at , which represents a -13.2% decrease from the current price of $4.61.
What is the overall RZLT consensus from analysts for Rezolute, Inc.?
The overall analyst consensus for RZLT is bullish. Out of 6 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are RZLT stock price projections?
Stock price projections, including those for Rezolute, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:54 AM UTC